Evidence mapPaperPMID 39304112Full record

ArticleRegulatory toxicology and pharmacology : RTP2024

Botanical-induced toxicity: Liver injury and botanical-drug interactions. A report on a society of Toxicology Annual Meeting symposium.

Igor Koturbash, R Philip Yeager, Constance A Mitchell, Stephen Ferguson, Victor J Navarro, Mary F Paine, Amy L Roe

Abstract readConference Proceedings
In one paragraph

Article in Regulatory toxicology and pharmacology : RTP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Igor KoturbashDepartment of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Center for Dietary Supplements Research, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; USP Botanical Dietary Supplements Admission Evaluation and Labeling Expert Committee, United States Pharmacopeial Convention (USP), Rockville, MD, USA.
R Philip YeagerOffice of Dietary Supplement Programs, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, USA.
Constance A MitchellHealth and Environmental Sciences Institute (HESI), Washington, DC, USA. Electronic address: cmitchell@hesiglobal.org.
Stephen FergusonDivision of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
Victor J NavarroDepartment of Medicine, Jefferson Einstein Medical Center, Philadelphia, PA, USA.
Mary F PaineDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Amy L RoeUSP Botanical Dietary Supplements Admission Evaluation and Labeling Expert Committee, United States Pharmacopeial Convention (USP), Rockville, MD, USA; Procter & Gamble Company, 8700 Mason-Montgomery Rd, Box 2006, Cincinnati, OH, 45040, USA.

Funding

NCCIH NIH HHS U54 AT008909NIGMS NIH HHS P20 GM109005
6 · The paper itself

Abstract

Botanical supplements and herbal products are widely used by consumers for various purported health benefits, and their popularity is increasing. Some of these natural products can have adverse effects on liver function and/or interact with prescription and over-the-counter (OTC) medications. Ensuring the safety of these readily available products is a crucial public health concern; however, not all regulatory authorities require premarket safety review and/or testing. To address and discuss these and other emerging needs related to botanical safety, a symposium was held at the Society of Toxicology Annual Meeting in Salt Lake City (UT) on March 11, 2024. The symposium addressed the latest research on botanical-induced liver toxicity and botanical-drug interactions, including new approach methods to screen for toxicity, challenges in assessing the safety of botanicals, and relating human adverse events to specific products. The presentations and robust panel discussion between the speakers and audience highlighted the need for further research and collaboration to improve the safety of botanical supplements and herbal products, with the ultimate goal of protecting consumer health. Although utility of many of the modern tools presented in the symposium requires further study, the synergistic efforts of diverse experts hold promise for effective prediction and evaluation of botanical-induced hepatotoxicity and botanical-drug interaction potential.

Indexed as

Chemical and Drug Induced Liver InjuryDietary SupplementsHerb-Drug InteractionsPlant PreparationsAnimalsHumansPlant Preparations3D liver microtissuesashwagandhabotanical dietary supplementsBotanical-drug interactionHepatotoxicityHerbal medicineKratomLiver injurySandwich-cultured human hepatocytesTurmeric

Identifiers

PMID39304112
PMCPMC11556352

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.